title: Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
abstract: OBJECTIVE
  To compare results of urinary cytology, quantitative detection of human complement factor H-related protein (BTA TRAK), and urinary fragments of cytokeratins 8 and 18 (UBC IRMA) with the recurrence status in patients with pTapT1 bladder cancer and to define the possible role of these methods in a surveillance protocol.
  
  
  METHODS
  We collected urine from 88 consecutive patients with primary pTapT1 tumors before the first transurethral resection (TURB) and before each follow-up cystoscopy. In all samples urinary cytology and quantitative BTA and UBC tests were performed. We compared results with recurrence status and with tumor characteristics in the case of recurrence. We constructed receiver operator characteristic (ROC) curves for quantitative methods. In addition, we evaluated individual cutoffs based on pretreatment levels.
  
  
  RESULTS
  During the mean follow-up of 16.96 months, we performed 313 cystoscopies, 93 of which were positive in 51 patients. The sensitivity and specificity of cytology, BTA, and UBC were 19.8% and 99%, 53.8% and 83.9%, and 12.1% and 97.2%, respectively. The sensitivity of pTis detection was 66.6%, 0%, and 100%, respectively. With cutoffs set to a sensitivity of 90%, the specificity of BTA and UBC dropped to 24.8% and 20.4%, respectively. Individually calculated cutoffs did not provide a significant benefit.
  
  
  CONCLUSIONS
  Because of high specificity and sensitivity in pTis detection, urinary cytology fulfills requirements for an adjunctive method to cystoscopy. Quantitative BTA and UBC tests have a low sensitivity in the detection of bladder cancer recurrence and cannot be used routinely to reduce the number of cystoscopies during follow-up.
authors.affiliation: Department of Urology, General Teaching Hospital, 1st Faculty of Medicine, Charles University, Postgraduate Institute, Praha, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Babjuk
authors.forename: V
authors.initials: V
authors.lastname: Soukup
authors.forename: M
authors.initials: M
authors.lastname: Pesl
authors.forename: M
authors.initials: M
authors.lastname: Kostírová
authors.forename: E
authors.initials: E
authors.lastname: Drncová
authors.forename: H
authors.initials: H
authors.lastname: Smolová
authors.forename: M
authors.initials: M
authors.lastname: Szakacsová
authors.forename: R
authors.initials: R
authors.lastname: Getzenberg
authors.forename: I
authors.initials: I
authors.lastname: Pavlík
authors.forename: J
authors.initials: J
authors.lastname: Dvorácek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000652:urine*; D014408:Biomarkers, Tumor / Q000652:urine*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy / Q000652:urine*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000652:urine; D011159:Population Surveillance / Q000379:methods*; D011237:Predictive Value of Tests; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy / Q000652:urine*; D019459:Urothelium
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C440529:UBC antigen; C112999:bladder tumor-associated antigen